BioAtla (NASDAQ:BCAB) Announces Earnings Results

BioAtla (NASDAQ:BCAB) announced its quarterly earnings data on Thursday. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.64, Zacks reports. The business had revenue of $6.50 million for the quarter.

BioAtla Stock Up 2.1%

BioAtla stock opened at $3.45 on Friday. BioAtla has a 12 month low of $3.12 and a 12 month high of $71.50. The stock has a market cap of $5.73 million, a P/E ratio of -0.08 and a beta of 0.78. The company’s fifty day simple moving average is $3.65 and its 200-day simple moving average is $5.86.

Institutional Trading of BioAtla

A number of institutional investors have recently bought and sold shares of the company. Woodline Partners LP purchased a new position in BioAtla in the first quarter valued at about $26,000. ADAR1 Capital Management LLC acquired a new stake in shares of BioAtla during the 4th quarter valued at about $104,000. Susquehanna International Group LLP lifted its holdings in shares of BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares during the last quarter. Jane Street Group LLC grew its stake in shares of BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after buying an additional 123,597 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of BioAtla in the 3rd quarter valued at approximately $235,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioAtla in a report on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $200.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.